KUALA LUMPUR, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - Tsuburaya Productions Co., Ltd. unveils an original illustration for the Ultraman Card Game by Yukinobu Tatsu, the manga artist behind the popular series “DAN DA DAN” that is currently being serialized in Shonen Jump+. Featuring the iconic character “Alien Metron The Hallucination Alien,” this artwork will appear on a promotional card for an upcoming product. This information was released at TSUBURAYA CONVENTION 2025, held on 13 & 14 September at Tokyo Dome City.■「Alien Metron The Hallucination Alien」The illustration depicts Alien Metron dashing through a city at dusk—eerie, yet full of humorous charm. This card will be distributed as a purchase bonus for Booster Pack Vol. 5 “Heroes of the Radiant Dawn” on 31 October 2025.Additionally, a new product type will be released on Friday, December 19, 2025. Titled “Ultra Deck 01 Ultraman Tiga & Ultraman Blazar,” this product will contain a preconstructed deck as well as official gameplay accessories, which will allow players to start playing the game immediately.■「Ultra Deck 01 Ultraman Tiga & Ultraman Blazar」This deck will feature the titular duo Ultraman Tiga and Ultraman Blazar. Alongside reprints of essential cards, this deck will also include cards with brand-new illustrations that will only be available in this product, making it a must-have for players and collectors alike. This epic team-up offers a new perspective on the Ultraman Universe, as these heroes have never appeared in previous Ultraman works together.Official gameplay markers and exclusive sleeves will also be included in this product. The official gameplay markers are cards that cannot be included in a deck, but will help to support game progression by marking changes clearly for both players. The limited-design sleeves will feature both Ultra Heroes together in a single illustration.●Booster Pack 05 Heroes of the Radiant DawnRelease Date：31 October 2025 (Fri)MSRP： MYR 18/pack (excluding tax)Contents- 12 cards per pack- 24 packs per display box- Exclusive PR card with Box purchase: Alien Metron The Hallucination Alien●Yukinobu Tatsu’s Profile 龍幸伸氏 プロフィールYukinobu TatsuIn 2010, he made his debut with “Seiji no Rokugo” in “Monthly Shonen Magazine”.In 2015, he released the one-shot “Renai Saibaihou” in Jump SQ.CROWN. After publishing two more one-shots, he began serializing “DAN DA DAN” for Shonen Jump+ in 2021. ■”DAN DA DAN”An occult battle and coming-of-age story that has sold more than 10 million copies since its release. The story follows Momo Ayase, a high school girl born into a family of spirit mediums, and her classmate Ken “Okarun” Takakura, an occult enthusiast, as they confront various supernatural phenomena. This series is currently being serialized on Shueisha's manga app "Shonen Jump+" (updated every Tuesday).●Ultra Deck 01 Ultraman Tiga ＆ Ultraman BlazarRelease Date：19 December 2025 (Friday)MSRP： MYR 105/pack (excluding tax)Contents-60 card pre-constructed deck (21 card types) ※Including reprints-13 Markers (5 Types)-1 Bonus pack（1 random special design marker (Total 6 types) -70 Sleeves of 1 Design※Product specifications are subject to change. Ultraman Card Game Product InformationThe Ultraman Card Game is a trading card game designed based on the Ultraman Universe and combines collectability with playability that appeals to both adults and children.Official Name: Ultraman Card GameDistributing countries and regions: Japan, Mainland China, South Korea, Taiwan, Hong Kong, Singapore, Malaysia, Indonesia, Vietnam, Philippines, Thailand, Australia, USA, Canada, Mexico.Distribution areas: Retail, toy stores, and trading card shops in distribution countriesOfficial Sitehttps://ultraman-cardgame.com/Official Social Mediahttps://x.com/ucg_enhttps://linktr.ee/ultramancardgame (List) Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月17日 - (亚太商讯 via SeaPRwire.com) – 在当下健康消费理念日益深入人心的时代，天然椰子水因其天然、健康、清爽的特性，受到消费者的广泛青睐。IFBH Limited（「IFBH」，6603.HK）作为该领域的领军企业，始终秉持创新与进取的精神，积极拓展业务版图，在激烈的市场竞争中脱颖而出，不断助力行业稳步发展。里程碑式合作 为品牌发展注入强心针9月15日，一场具有里程碑意义的合作在商业领域拉开帷幕。IFBH与央企中粮集团旗下的中粮名庄荟正式签署战略合作协议，根据协议内容，双方将采用线上线下双轨并行的渠道拓展策略，全方位强化Innococo 100%椰子水的分销体系。这一合作，不仅为旗下品牌Innococo 100%椰子水引入了一位重磅的全新分销伙伴，同时亦为公司的品牌发展注入了一剂强心针。据悉，中粮名庄荟是中国大型央企中粮集团在酒类及高端饮品渠道的旗舰平台。中粮名庄荟凭借遍布全国的经销网络、全品类渠道资源和深厚的供应链管理能力，长期服务于多家国际高端品牌，在国内酒水与高端饮品领域树立了卓越的声誉，成为最具影响力的分销平台之一。此次与IFBH的合作，无疑是强强联合，将为Innococo品牌在中国市场的发展带来无限可能。此次战略合作，意义深远。一方面，充分体现了IFBH首席执行官Pongsakorn Pongsak先生高瞻远瞩的战略眼光和精准布局，为公司的长远发展构筑稳固根基。另一方面，通过中粮名庄荟强大的分销网络，Innococo 100%椰子水能够更迅速、更广泛地进入消费者的视野，满足市场需求，实现市场份额的大幅跃升，进而巩固IFBH在中国椰子水市场的领先地位，为公司的长期发展注入源源不断的动力。 业绩稳步增长 成功纳入港股通彰显实力得益于积极的业务拓展和精准的市场策略，IFBH业绩呈现出显著增长态势。中期财报显示，2025年上半年，公司实现总收益94.5百万美元，同比增长31.5%，增速跑赢行业平均水平；毛利规模达31.8百万美元，同比提升15.3%，毛利率维持在健康区间；经调整溢利净额18.9百万美元，同比增长13.9%，盈利质量稳步提升。除了亮眼的业绩，IFBH进一步迎来了资本市场层面的利好消息。近日，沪深交易所发布公告，宣布调整港股通标的证券名单，其中，IFBH凭借出色的基本面与市场声誉，成功纳入港股通标的证券名单，并于9月8日起正式生效。这一重大利好消息，标志着符合资格的内地投资者可通过沪港通和深港通机制便捷地投资IFBH的股票，不仅有利于改善公司股票的流动性，吸引更多投资者关注，还将有助于提升公司的市场估值，进一步增强公司在资本市场的影响力。从行业角度来看，随着消费者对健康饮品需求的持续增长，大中华即饮软饮料市场展现出强劲的增长潜力。按零售额计算，其2024年市场规模达1,384亿美元，预计将以7.1%的复合年增长率增至2029年的1,947亿美元。其中，椰子水饮料作为增长最快的细分领域，预计将以19.4%的复合年增长率从2024年的1,093.3百万美元增长至2029年的2,651.8百万美元，市场前景一片光明。IFBH Limited作为行业的领导者，凭借其强大的品牌影响力、优质的产品品质和完善的销售网络，有望持续享受行业增长带来的红利。未来，公司将继续坚持创新驱动，不断提升产品品质，加强品牌建设，拓展市场份额。同时，不断加强与合作伙伴的深度合作，实现资源共享、优势互补，驱动公司业绩及股价再上新台阶。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

“The Vicissitudes of Life” Celebrates the Transformative Power of Art in Dialogue, Reflection and PeacebuildingPENANG, Malaysia, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - Renowned humanitarian-artist Professor Lin Xiang Xiong (“Professor Lin”) and founder of the Lin Xiang Xiong Art Gallery in Penang, presented his latest exhibition, “The Vicissitudes of Life”, at the historic Hôtel de l’Industrie in Paris from 10 to 13 September 2025.(L-R) Jean-Pierre Raffarin, former French Prime Minister and founder of Lin Xiang Xiong Art Gallery, Professor Lin Xiang XiongThe exhibition received strong support from key French institutions, with former French President François Hollande serving as Honorary Patron, and former French Prime Minister Jean-Pierre Raffarin personally attending the opening. Featuring 25 original works by Professor Lin, the exhibition explored three themes - anti-war, anti-poverty, and anti-pollution - and vividly embodied Professor Lin’s vision of “Art for Peace”, a concept that transcends aesthetics and seeks to inspire moral reflection and intercultural understanding.Distinguished speakers exchange views on art, culture, and peace during the academic symposium held as part of Professor Lin Xiang Xiong’s exhibition “The Vicissitudes of Life” in Paris.During the exhibition, a high-level academic symposium was held, bringing together leading international scholars, philosophers, and cultural leaders to reflect on “Intercultural Dialogue at the Crossroads” and “Rebuilding the Concept of Peace through Art.” Distinguished speakers included French writer and human rights activist Marek Halter, eminent philosopher and sinologist François Jullien, intellectual publisher François L’Yvonnet, Swiss curator and sociologist Barbara Polla, special adviser to the President of the Arab World Institute Claude Mollard, cultural diplomacy advisor Yves Marek, and retired French Air Force General Étienne Copel. Throughout the discussions, Professor Lin shared his unique insights on the times, on art, and on the essence of peace, sparking strong resonance and deep dialogue.On 12 September, the inaugural “Lin Xiang Xiong Art for Peace Prize” ceremony was held with great success. The competition drew 1,883 entries from 100 countries around the world, far exceeding expectations. This overwhelming response underscored the wide recognition of Professor Lin’s “Art for Peace” advocacy, echoing the common aspirations of today’s world. Professor Lin announced that the award will be established as a biennial event, continuing as a major artistic initiative dedicated to peace.The exhibition and symposium attracted a full house at the historic Hôtel de l’Industrie in Paris.“This exhibition is more of an awakening of thought than a presentation of art,” said Professor Lin Xiang Xiong. “Every brushstroke is a testimony of time, a silent dialogue between past and present, pain and healing. Whether through the exhibition or the establishment of the Peace Prize, I hope art is not merely for admiration but can truly touch hearts, serve as a bridge between cultures, and awaken the soft conscience deep within humanity.”Exhibition view of “The Vicissitudes of Life”The exhibition also marks a milestone in Professor Lin’s artistic journey and heralds the opening of the Lin Xiang Xiong Art Gallery in Penang, scheduled for mid-December 2025. Covering 8,000 square meters, the gallery will house Professor Lin’s major works and also providing a platform for emerging artists to pursue their dreams. It will stand as one of the largest private art galleries in the region, strengthening Malaysia’s role as a hub of cultural diplomacy and intercultural understanding in Southeast Asia.Through “The Vicissitudes of Life,” Professor Lin once again demonstrates that art is a messenger of thought and conscience. With clarity, he advocates peace, and as an artist, he chooses his own path - through the soft power of culture, through words, and through his brush - to voice his deep concern for war, pollution, and poverty. With art as his language, he calls upon fellow artists to join his cause, uniting their strength to speak out for peace and the future of humanity.Download high-resolution images from this LINK.About Lin Xiang XiongProfessor Lin Xiang Xiong is a renowned artist, entrepreneur, and advocate for global security through art. As President of the Global Chinese Arts & Culture Association, a researcher at the Chinese Academy of Art, and a visiting Professor at Peking University, Lin's work crosses disciplines and borders, connecting Eastern and Western cultures.After leaving China for Singapore in 1956, Lin pursued art studies at the Academy of Arts (1965–1968). Success in business, particularly in the mining industry in Malaysia, funded his travels, art remained his personal refuge and lifelong passion.His painting style is a dynamic combination of abstraction, traditional techniques, and contemporary social commentary, touching on themes such as climate change, war, forced migration, and the human condition. Despite being involved in the commercial field, Lin has never neglected his commitment to art as a force for good.Professor Lin is an outspoken advocate of the power of the arts in promoting peace and unity. In 2016, he curated a UNESCO exhibition titled "Art for Peace – Cultural Dialogue between East and West", which calls on artists to rise up as peacemakers, reduce inequality, and protect the planet. These events resulted in important cultural dialogues that have been documented and archived by UNESCO. Professor Lin has published numerous works, including 8 collections of paintings and 27 volumes of essay and art criticism.For media information, kindly contact:Triven Marketing Group, for Lin Xiang Xiong Art GalleryJazzmin WanTel: +6 017 289 4110Email: j.wan@swanconsultancy.biz Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Calgary, Canada, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - Karbon-X Corp. (OTCQX:KARX) (“Karbon-X" or the “Company”), a vertically integrated climate solutions company, today announced that it has filed its Form 10-K with audited financial results for the fiscal year ended May 31, 2025.The full filing is available under the Company’s profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview Operational and Strategic highlights for Fiscal Year 2025Completed the acquisition of ALLCOT Group, expanding Karbon-X’s global footprint and integrating world-class expertise.Launched trading operations, marking a critical milestone in validating the Company’s business model and initiating its revenue-generating activities. Entered landmark partnerships with major energy producers and with the BK Dukes, reflecting strong market confidence in Karbon-X’s vision and capabilities.Financial Highlights for Fiscal Year 2025 Revenue surged to $3.16 million, up from $0.41 million in the prior year, marking the first full year of active carbon credit trading.Recognized $3.86 million in deferred revenue from forward carbon credit contracts, including contracts acquired through the ALLCOT transaction.The ALLCOT acquisition expanded Karbon-X’s verified emissions pipeline and positioned the Company for multi-jurisdictional credit monetization. Entered revenue-generating agreements with major energy producers and the BK Dukes, contributing to $3.79 million in receivables from forward carbon credit sales.“2025 was a pivotal year for Karbon-X, marked by the acquisition of ALLCOT Group, the launch of our trading operations, and new partnerships that strengthened our position in the global carbon market. These achievements are reflected in our financial results, which highlight both the momentum we’ve built and the foundation we’ve established for long-term growth. We are confident in our strategy and committed to delivering lasting value for shareholders and the planet.” – Chad Clovis, CEO of Karbon-XLooking AheadThe Company intends to continue to execute on its growth strategy, with a focus on expanding its role in both compliance and voluntary carbon markets, advancing new partnerships, and scaling its portfolio of climate solutions. Management believes Karbon-X is well-positioned to capitalize on increasing demand for trusted climate solutions and to deliver long-term value for shareholders. About Karbon-XKarbon-X Corp. (OTCQX:KARX) is a vertically integrated climate solutions company delivering end-to-end climate solutions across both compliance and voluntary markets. From project origination and emissions quantification to third-party verification, credit issuance, and market distribution, Karbon-X ensures transparency and impact at every step. Karbon-X makes trusted climate action accessible not only to businesses and institutions, but also to individuals and everyday people who want their choices to create lasting impact.Forward Looking Statement This news release contains forward-looking statements, including but not limited to expectations related to Karbon-X Corp.’s financial performance, business strategy, growth plans, and market positioning. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are subject to change, and Karbon-X Corp. assumes no obligation to update them, except as required by law.Contact: Adriana EbellInterim CFOKarbon-Xa.ebell@karbon-x.com Emma CaputoVP of MarketingKarbon-Xec@karbon-x.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 17, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic diseases, announced that data from the Phase 3 SYMPHONY 2 trial evaluating the safety and efficacy of HTD1801 in patients with type 2 diabetes mellitus (T2DM) is being presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.HTD1801, is a first-in-class anti-inflammatory metabolic modulator that activates AMPK and inhibits the NLRP3 inflammasome. These pathways converge at the nexus of metabolic dysregulation beyond glucose control and chronic inflammation. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of HTD1801 compared to placebo in patients with T2DM inadequately controlled with metformin. The primary endpoint of Symphony 2 was change from baseline in HbA1c to Week 24 compared to placebo. Secondary endpoints explored effects on cardiovascular, metabolic, and renal comorbidities to assess it’s potential as a comprehensive Cardiovascular-Kidney-Metabolic therapy.Eligible patients were randomized 2:1 to HTD1801 1000 mg BID (N=365) or placebo (N=184). The study met the primary endpoint at Week 24, with HTD1801-treated patients achieving an LS mean change in HbA1c of -1.21% compared to -0.68% with placebo (LS mean diff: -0.53, p

PHILADELPHIA, PA, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit, a global leader in healthcare workforce development, today launched two new global credentials for healthcare workers specializing in rehabilitation, habilitation, and restorative care.The Certified Global Health Worker-Rehabilitation (CGHW-R) and the Certified Global Health Worker-Rehabilitation Advanced (CGHW-RA) have been developed specifically for eligible health workers worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination. These credentials, along with the Certified Global Nurse-Rehabilitation (CGN-R) that TruMerit established last year, are intended to advance and improve services for the more than two billion people worldwide who need this care.The CGHW-RA credential was developed for those with a degree or diploma in a rehabilitation field. These include clinicians, educators, and instructors with physiotherapy, occupational therapy, speech language pathology, or other rehab-related specializations.The CGHW-R credential was designed for those who have rehab health experience but have not completed post-secondary education in an area of rehab specialization. These would include technicians, assistive personnel, nursing assistants, and home or community health aides working in rehabilitation, habilitation, and restorative care settings.In addition to education and degree requirements, candidates for these credentials must have at least two years of work experience in a rehabilitation, habilitation, or restorative care setting during the last five years. Upon verification of their credentials by TruMerit, they must pass a proctored exam that is offered at more than 1,000 test centers worldwide.In 2019, CARF International, a non-profit organization that accredits rehabilitation care providers worldwide, alerted TruMerit (known then as CGFNS International) about the growing demand for validating practice competence of the rehabilitation health workforce and raising standards across the care continuum. TruMerit and rehabilitation experts from across the world began the process to create exam-based global certifications for healthcare professionals working in rehabilitation, habilitation, and restorative care settings. The process has included more than 200 subject matter experts from 45 countries from all world regions and income levels."Caring for the huge and growing population of persons living with a disability is one of the most pressing issues facing healthcare today. By validating the knowledge and skills of those who devote their careers to providing this care, global credentials will help drive efforts to expand and equip this vital workforce to meet the challenges of the future. We are grateful to the global team of rehab care experts who helped make these credentials possible," said Julia To Dutka, Chief of TruMerit's Global Health Workforce Development Institute, which is leading the initiative.View more information on TruMerit's global rehab certification program.Additionally, last month TruMerit unveiled its Certified Global Nurse (CGN) credential for first-level, general nurses (RNs), along with a reinvented Nurse Qualifying Exam.About TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers-and those who license and hire them-by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers.Contact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月17日 - (亚太商讯 via SeaPRwire.com) – 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能疗法以解决代谢性疾病未满足临床需求的创新药公司，宣布在第61届欧洲糖尿病研究协会（EASD）年会（奥地利维也纳），口头报告2型糖尿病（T2DM）患者中评估HTD1801有效性和安全性的3期临床研究（SYMPHONY 2）数据。HTD1801是全球首创抗炎代谢调节剂，通过激活AMPK并抑制NLRP3炎症小体的双重作用机制，为患者带来远超血糖控制的综合性代谢获益。这项随机双盲、安慰剂对照的临床研究旨在评估HTD1801与安慰剂相比在二甲双胍控制不佳的T2DM患者中的有效性和安全性。SYMPHONY 2的主要终点为与安慰剂相比治疗24周后HbA1c相对于基线的变化。次要终点包括对心血管、代谢及肾脏共病的危险因素干预，以评估HTD1801作为心肾代谢系统疾病（CKM）的综合治疗潜力。SYMPHONY 2试验中，患者按2:1随机分配至HTD1801组（1000mg一天两次，N=365）或安慰剂组（N=184）。该研究达到了主要终点，HTD1801治疗组第24周HbA1c的最小二乘（LS）均值变化为 -1.21%，安慰剂组为-0.68%（LS均值差异：-0.53%， p＜0.0001）。33%的患者在HTD1801治疗24周后达到HbA1c＜7%的控制目标，安慰剂组仅有11%（p＜0.0001）。治疗24周后，HTD1801还显著改善了餐后血糖和空腹血糖。事后分析显示在合并轻度肾损的患者中，HTD1801可改善eGFR，提示肾脏保护的潜力。此外，HTD1801显著降低了预设次级终点中血脂和炎症标志物。与之前临床研究结果一致，HTD1801表现出良好的安全性和耐受性。HTD1801组的严重不良反应发生率为4%，安慰剂组为6%。研究期间未发生严重低血糖事件。该研究对应的开放标签延长期试验正在进行中，将进一步验证HTD1801综合疗效的持久性。摘要标题：Symphony 2：一项评估HTD1801治疗二甲双胍控制不佳的2型糖尿病患者的随机、安慰剂对照的临床3期研究报告编号：62报告时间：2025年9月16日，周二，下午2:45（欧洲中部夏令时）报告形式：口头报告演讲者：纪立农 教授临床试验的主要研究者，前国际糖尿病联盟（IDF）副主席、北京大学糖尿病中心主任、北京大学人民医院内分泌和代谢科主任纪立农教授指出：“HTD1801 是一款具有源头创新性的小分子药物，具有独特的双重作用机制，能够同时激活 AMPK和抑制 NLRP3 炎症小体。在已经完成的3期临床研究中，该药物展现出非常平稳且显著的降糖效果而且安全性良好。除此之外，研究还观察到 HTD1801 具有降糖之外的多重获益，包括降低血脂水平、减轻炎症反应，以及改善肾脏功能等相关指标。作为一种口服降糖药物，HTD1801 在改善心血管危险因素与保护肾脏功能方面也展现出潜力，值得进一步探索其在心肾保护方面的潜力”君圣泰医药的创始人、董事长兼首席执行官刘利平博士表示：“SYMPHONY 2是我们在2型糖尿病领域开展的第二项3期临床研究，已成功达到主要临床终点，充分表明HTD1801临床疗效的一致性和可靠性。值得关注的是，HTD1801不仅展现出显著的血糖获益，同时在心血管和肾脏方面亦为T2DM患者带来潜在获益。随着3期临床试验的顺利进行，我们今年将在中国递交NDA申请，为广大糖尿病患者带来新的治疗选择，填补该疾病领域创新疗法重大未满足需求。”关于HTD1801HTD1801是一款全球首创的新分子实体，旨在解决心肾代谢系统疾病（CKM）。HTD1801是口服抗炎及代谢调节剂，作为单一分子具有独特双机制 ，通过激活AMPK及抑制NLRP3炎症小体发挥其生物学活性，有效解决代谢性疾病。全球多项临床结果验证HTD1801一药多效的特性，为患者带来综合获益，包括改善胰岛素抵抗、血糖控制、血脂降低、肾脏获益、体重减轻、肝脏获益及抗炎等。基于此，HTD1801有潜力成为CKM领域的基础性治疗药物。关于君圣泰医药君圣泰医药（股票代码：2511.HK）是一家专注于代谢性疾病的创新生物医药公司。立足源头创新，公司致力于开发代谢性疾病的突破性疗法，为全球患者提供标本兼治、综合获益的解决方案。公司已建立100%自主知识产权的全球化产品管线，已在多个国家和地区开展了针对多项适应症的临床研究，相关成果获得国际学术界和监管机构的认可。公司核心产品HTD1801是全球首创的双靶点新分子实体，已获得美国食品药品监督管理局（FDA）2项快速通道与1项孤儿药资格认定、以及2项“重大新药创制”国家科技重大专项。 更多信息，请访问公司官网：www.hightidetx.com， 或联系公司品牌部: pr@hightidetx.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Sept 17, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI), in collaboration with the Dutch Ministry of Defence and the Dutch Ministry of Economic Affairs, will host its second Blue Magic Netherlands (BMNL) event on November 18, 2025. BMNL 2025 follows the successful first event in 2024 and will take place at the MELT at Avular building, a world-class venue for technology interchange near Brainport Eindhoven, the center of the Dutch high-technology manufacturing industry. The registration site can be accessed at www.ga-asi.com/blue-magic-netherlands-2025."The first BMNL event was a huge success for Dutch industry," said Brad Lunn, managing director for GA-ASI. "We've built strong investment opportunities with Dutch companies - including Arceon, Emergent Swarm Solutions, and Saluqi Motors - and now we're looking to build on that success at BMNL 2025."Blue Magic Netherlands fosters technology ideation and implementation within the Dutch industrial ecosystem. GA-ASI is inviting Netherlands-based technology and aerospace companies, big and small, to apply for a chance to pitch transformative next-gen solutions that could shape the course of commercial and defence technologies. This event brings together leaders in advanced technology, aerospace, business, and government in a single Dutch forum to explore emerging technologies that address the world's most pressing defence and security challenges. GA-ASI supplies its MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force.Along with partners Brainport Development Eindhoven, Lockheed Martin Ventures, Brabant Development Agency and the Netherlands Industries for Defence & Security (NIDV), GA-ASI will accept proposals to present a broad range of technologies. Participating in this transformational event provides an ideal opportunity to connect with funding sources and collaborate with industry leaders. Companies and individuals wishing to only join the audience and network are welcome to register as well.Companies interested in presenting their capabilities can submit a pitch proposal. GA-ASI and other participants will hear technology pitches followed by a lively panel discussion. Networking opportunities will also be available where participants can meet with other high-tech businesses and industry leaders to see if their capabilities can be leveraged in new and useful ways. Focus areas for this year are Intelligent Systems - Artificial Intelligence (AI)/Machine Learning and Autonomy, Smart Materials - Advanced Materials and Manufacturing, Sensors, Space, and Counter-UAS.Companies interested in presenting their capabilities must submit pitch proposals in PDF format by no later than October 10, 2025. Companies selected to present pitches will be notified on November 3, 2025.To submit a pitch proposal or register to attend in person or virtually, please visit the event website at www.ga-asi.com/blue-magic-netherlands-2025.BMNL organizers will also host several virtual workshops covering a variety of topics relevant to defence technology start-ups. These workshops will be listed on the event website and are available for the entire Dutch innovation ecosystem.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com